INSTRUCTIONS FOR AUTHORS

Cancer Research is the official organ of the American Association for Cancer Research, Inc., and is devoted to the publication of significant, original research in the fields of cancer research and cancer-related biomedical science. The Editors will be happy to consider manuscripts from any country in the world that contain material falling within the Journal's publication scope. Only those papers that report results of novel and timely studies and that meet high standards of scientific quality will be accepted. Such papers will be subjected to stringent review and are published within about three months after acceptance.

When a manuscript is received for consideration, the Editors assume that no similar paper, other than an abstract or preliminary report, has been or will be submitted for publication elsewhere. Editorial decisions, forwarded from the Editorial Office to authors, are rendered as promptly as possible consistent with thoroughness of review.

Journal policy requires that a single manuscript processing fee of $50 be assessed for all manuscripts, regardless of the number of resubmissions required, to defray the expenses incurred in review. Payment of this processing fee should not accompany the manuscript; invoice will be mailed with acknowledgment of receipt at the Editorial Office. Editorial review will not be delayed for receipt of payment.

Contributions must be submitted in quadruplicate (the original typescript and three clear copies, with at least two sets of original illustrations) to Dr. Sidney Weinhouse, Editor, Cancer Research, Editorial Office, Fels Research Institute, Temple University School of Medicine, Philadelphia, Pa. 19140 (Telephone: 215-221-4720). Papers should be submitted only by an author, preferably the senior author, who should indicate in a covering letter the exact address to which all related correspondence should be sent and a telephone number at which the author can be reached. The original plus a photocopy of this letter are required. If the manuscript contains any quoted information conveyed by either personal communication or release of unpublished experimental data, the covering letter should state specifically that authorization to use this material has been given.

The Editorial Office cannot accept collect telephone calls from authors.

Authors are urged to read carefully and follow these instructions to minimize the time and expense involved in processing manuscripts.

Revised Manuscripts

Revised manuscripts should be submitted in triplicate, with two sets of original illustrations. A covering letter in duplicate must accompany all revised manuscripts and indicate clearly what alterations have been made in response to the reviewers' comments. Satisfactory reasons should be given for noncompliance with any of the recommendations of the Editors.

Categories of Publication

The following types of manuscripts are accepted: (1) Papers containing results of original experimental, clinical, or statistical studies that are sufficiently well documented to be acceptable to the critical reader. (2) Concise reviews on subjects of importance to cancer researchers. Such articles are given particularly stringent editorial evaluation before acceptance. (3) Communications that are brief and of unusual timeliness and significance. These papers are given especially rigid and rapid review and, if deemed acceptable, are published one month earlier than regular papers. (4) Letters to the Editor which deal with issues of importance to cancer researchers. If experimental data are included, these should be kept to the minimum required for adequate understanding for proper literature retrieval. Included under this category are commentaries on manuscripts published in the Journal. If accepted, replies by the authors are invited for simultaneous publication. (5) Brief reports of meetings, symposia, and conferences related to cancer research. (6) Proceedings of symposia, published as external supplements to the Journal, the full expenses of which are assumed by the sponsoring agency. (7) Brief announcements of scientific meetings of interest to readers, of courses in cancer-related biomedical science, and of the availability of fellowships and scholarships. These should be submitted at least 3 months prior to the expected month of issue. (8) Books received at the Editorial Office are listed; the Journal does not publish book reviews.

Format and Style

Papers should conform strictly to Journal style. A recent issue of Cancer Research will provide authors with assistance in the proper arrangement of papers. Manuscripts are to be written in clear, grammatical English. Papers that are not in good idiomatic English will be returned to the author without review. Investigators not fluent in the English language can avoid long delays in publication by conferring with colleagues knowledgeable in written English expression in the preparation of their manuscripts.

Instructions for Authors

Data must be presented concisely. Large masses of data of peripheral significance to the main thesis of the investigation will not be published in Cancer Research but may be deposited by the author in the National Auxiliary Publications Service, c/o Microfiche Publications, 440 Park Avenue South, New York, N. Y. 10016. The manuscript should contain a footnote that indicates how this ancillary material can be obtained. Forms needed to store these data are available from the Editorial Office. Such data should be submitted for review along with the manuscript and will be returned to the author upon acceptance.

Authors should edit their typescripts to eliminate unnecessary words and phrases and to detect typographical errors, inconsistencies in the use of tenses, or misleading, ambiguous phrases. Laboratory slang as well as terminology and abbreviations not consistent with internationally accepted guidelines should be avoided.

The manuscript should be typed on 21.6- x 28-cm (8½- x 11-inch) paper with double spacing throughout, allowing for ample margins. Consecutive numbering of all pages is requested, with the title page as page 1. The typescript should be arranged in the following order: (a) title, (b) author(s) and complete name(s) and location(s) of institution(s) or laboratory(ies), (c) running title, (d) footnotes, (e) text, (f) tables, (g) legends for all illustrations (charts and figures), (h) illustrations, and (i) other subsidiary material. Numbered and lettered sections in the text should be avoided. The appropriate location for each table and illustration should be indicated by marginal notes. Simple chemical formulas or mathematical equations should be presented in a form that allows their reproduction in single horizontal lines of type; more complicated mathematical formulas or chemical structures difficult to set in type should be provided in the form of India ink drawings or glossy photographs for camera-ready reproduction.

Title. Titles should be brief but informative, and limited if possible to about 100 characters. It is important for literature retrieval to include in the title the key words necessary to identify the nature of the subject matter. Use of expressions such as "Studies on . . ." or "Observations of . . ." should be avoided, since they are imprecise and not sufficiently informative. Titles in the form of declarative sentences are not acceptable. Chemical formulas or abbreviations should not be used. Subtitles, whether set off by Roman numerals or punctuation, are not permitted, as these present difficulties for indexers. If the paper is one of a series, a footnote to this effect may be included.

Authors and Their Affiliations. Authors are urged to include their full names, complete with first and middle names or initials. This request is made in accordance with the recommendation of the IUB Commission of Editors of Biochemical Journals because confusion often arises when authors are identified by surname and initials only. Authors' academic degrees should not be included. The full names of institutions and subsidiary laboratories should be given, together with a useful address (including postal number). If several authors and institutions are listed on a paper, it should be clearly indicated with which department and institution each author is affiliated.

Running Title. A brief running title should be provided, not to exceed 50 characters.

Footnotes. Lengthy footnotes are discouraged since the same information can in most instances be presented more effectively in the text.

Footnotes to the title page and text are to be designated consecutively with superscript Arabic numerals. A footnote to the title should contain information on financial support, including the source(s) and number(s) of the grant(s). Authors should also include a footnote designating to whom reprint requests should be addressed. An all-inclusive abbreviation footnote should contain a definition for every nonstandard abbreviation used in the paper.

For footnotes to tables, see section on Tables below.

Abstract. The Abstract, to appear at the beginning of the paper, should be concise, yet indicative of the content of the paper. As Abstracts are often photocopied directly by the secondary services, they should recapitulate in abbreviated form the purpose of the study and the experimental technique, results, and interpretations of the data. The inclusion of data on the number of test subjects and controls, strains of animals or viruses, drug dosages and routes of administration, tumor yields and latent periods, length of observation period, and magnitude of activity is recommended. Vague, general statements such as "The significance of the results is discussed," or "Some physical properties were studied," are uninformative and not acceptable. Abbreviations should be kept to an absolute minimum; however, if they are needed, they must be properly identified so as to make the Abstract independent of the text.

Introduction. It is not necessary to include all of the background literature in this section. Brief reference to the most pertinent papers generally suffices to acquaint the reader with the findings of others in the field and with the problem or question to which the author's particular investigation is being addressed.

Materials and Methods. Explanation of the experimental methods should be brief but adequate for repetition by qualified investigators. Procedures that have been published previously should not be described in detail but merely cited in appropriate references. Only new and significant modifications of previously published procedures need complete exposition. The sources of special chemicals or preparations used should be given along with their locations [city and state (country if foreign)].

Results. This section should include a concise textual description of the data presented in tables, charts, and figures. Excessive elaboration of data already given in tables and illustrations should be avoided. The Results and Discussion sections may be combined if, by so doing, space is saved or the logical sequence of the material is improved.

Discussion. In this section, the data should be interpreted concisely without repeating material already presented in the Results section. Speculation is permissible, but it must be well founded.

References. Any recent issue of the Journal can serve as a model for style of references. It is important that the references be typed in double-spaced form to ensure accurate copy editing. References should be arranged in alpha-
Instructions for Authors

betical order and should include all authors' names (with initials). The bibliography should be limited to only those citations essential to the author's presentation. When comprehensive review articles are available, they are preferred to many separate references (an exception to this rule would be if the manuscript being prepared is a Review).

Before submission of the paper authors should verify the accuracy of all references and should check that all references have been cited in the text.

Journal articles and serial compendia. The complete title, journal, volume number, inclusive pages, and year should be given. Serial compendia, such as Advances in Cancer Research and the Annual Review of Biochemistry, which appear annually in numbered sequence, should be cited as journals rather than books, thus omitting the names of publishers and editors. Chemical Abstracts should be consulted for abbreviations of journals and serials.

Books and chapter citations. Citation of a specific chapter or article in a book should carry the author(s) of the chapter, its title, editor(s) of the book, book title, edition, volume, inclusive pages of the chapter, location and name of the publisher, and year. For references to complete books, give all of the above information that is pertinent.

Papers in press and unpublished material. Papers in press may be listed among the references with the journal name and tentative year of publication. References to papers in preparation or submitted for publication should be cited in a footnote, not in the References section; unpublished data or personal communications should be given in parenthetical form in the text. The names of all authors should be given, along with titles if possible. Material conveyed by "personal communication" may be used only if permission for its publication and verification of the wording of the citation have been obtained.

Addenda. Data acquired after acceptance of the paper, by the authors themselves or by others, cannot be added to the text. An addendum may be added in proof upon approval by the Editor. Addenda should be kept extremely brief. The full expense of printing an addendum will be charged to the author.

Tables. Tables should be constructed to fit within a single Journal column (8.9 cm or 3 1/2 inches). This will be enforced with few exceptions because of the Journal's budgetary constraints. Tabular material should not duplicate data already presented in the charts. Unnecessary columns of data that can easily be derived from the rest of the results in the table should not be included. Large masses of individual values should be avoided; instead, these should be averaged and an appropriate designation of the dispersion such as standard deviation or standard error included.

Authors are obliged to indicate the significance of their observations by appropriate statistical analysis; tables without such information are not acceptable.

Every table must have a descriptive title and an explanatory paragraph that clearly gives the experimental details for understanding by the reader without reference to the text. Each column must carry an appropriate heading and, if numerical measurements are given, these units should be added to the column heading. Tables should be numbered with Arabic numerals and table footnotes should be indicated with superscript italic letters ("a", "b", etc.).

All units of measurement and concentration should be clearly designated. Exponential terminology is discouraged (the term mM is preferable to 10^{-3} M). If exponents are absolutely unavoidable in column headings, the quantity expressed should be preceded, not followed, by the power of 10 by which its value has been multiplied, i.e., 10^{-3} \times concentration (M). This will prevent confusion as to whether the quantity should be multiplied or divided to obtain the correct value.

Charts. Line-cut illustrations (graphs and drawings) are to be designated charts. Flow diagrams and complex biochemical structures should be professionally prepared (not simply typewritten) and considered charts.

Graphs should be used sparingly and only when a salient point needs illustration. Straight-line functions such as relationships between concentration and absorbance, or Lineweaver-Burk plots when these are linear, should instead be described in a few lines in the text. To conserve space each chart should include those curves that may appropriately appear together.

The use of exponents for labeling coordinates in charts is considered ambiguous and should, if at all possible, be avoided. If exponents must be used, the quantity expressed should be preceded by the power of 10 by which its value has been multiplied, i.e., 10^{3} \times concentration (M). The form "Concentration (M \times 10^{-3})" is not acceptable. If powers of 10 are used, the legend should designate how the quantity is to be calculated (whether multiplied or divided) to give the correct value.

Preparation of charts. Charts must be drawn with professional instruments and may be on Bristol board, tracing paper or cloth, or coordinate paper printed in light blue. Charts should not be mounted on heavy cardboard. Clear, glossy prints are acceptable in lieu of original drawings, provided that all parts of the chart are in focus. X-ray films or Polaroid photographs are not acceptable. If original drawings are submitted, an overall size of not more than 21.6 x 28 cm (8 1/2 x 11 inches) is required.

Except for especially complicated drawings showing large amounts of data, all charts will be reduced to one-column width (8.9 cm or 3 1/2 inches) or less. It is the responsibility of the author to see that the abscissas, ordinates, lines, and especially the symbols are sufficiently large so that when the charts are reduced to the size of a single column, the letters and numbers will be at least 1.5 mm high and the smallest part of the illustration will be discernible. In original charts, this can be accomplished by having the minimum height for lower-case letters 5 mm; numerals and upper-case letters 6 mm; and symbols within the drawings 5 mm. The thickness of ruled lines on charts is also vital for clear presentation of the data. Size recommendations for lines are as follows: #1 Leroy for graph grids, bonds, and arrows; #2 Leroy for graph borders or reference lines; and #5 Leroy for graph curves or emphasis lines.

Points of observation should be denoted with different symbols rather than with different types of lines; their significance can be explained directly in the body of the
Instructions for Authors

chart or in the legend. Only those common symbols for which the printer has type \( \times, \circ, \bullet, \square, \blacksquare, \Delta, \triangle, \Theta \) should be used.

Charts should be ruled off on all four sides close to the area occupied by the curve, and abscissas and ordinates should be clearly marked with appropriate units. Explanations of the coordinates should not extend beyond the respective lines. If a chart contains a left- and a right-hand ordinate, explanation of the left ordinate should read in the upward direction and that of the right ordinate should read downward. Titles printed outside the confines of the charts waste space; all of this information can easily be included in the legend.

Each chart should be labeled in pencil on the reverse side with Arabic numerals and the first author’s name.

Chart legends. Legends are required for all charts. They should briefly describe the data shown; details in the text need not be repeated. Each legend should adequately identify all units, abbreviations, mathematical expressions, abscissas, ordinates, and symbols.

Figures. Because halftone illustrations (photomicrographs and photographs) are expensive to reproduce, only those photographs that are absolutely essential to the clarity of the presentation can be accepted.

It is often difficult for the printer to judge accurately the amount of reduction possible with electrophoretic patterns. Therefore, this material should be submitted in reduced form ready for photoreproduction.

Color photographs are discouraged and will be published only if the Editors deem them indispensable. The complete expense of reproducing such photographs will be charged to the author. Current estimates for color reproduction can be obtained by corresponding with the Editor.

Preparation of plates. Photographs should be mounted on "plates" of white cardboard; the overall dimensions of photographs on a given plate should not exceed 18.4 x 22.4 cm (7\( \frac{1}{4} \) x 9 inches). All photographs should be correctly exposed, sharply focused, and submitted on glossy white paper.

Karyotypes should be presented in the form of cardboard plates onto which chromosome sections from an original photomicrograph are pasted. This "original" is needed for clear Journal reproduction. The back of the plate should indicate how much it can be reduced in size if published. For review purposes, two additional glossy photographs are requested.

Considerable space may be saved by suitably cropping figures so that 4 to 6 photographs can be presented on one plate. Plates with only single photographs are not acceptable and will be returned for cropping or reduction unless the authors can justify their necessity.

Tooling (thin white lines) between the photographs should be uniform. Figure numbers, in Arabic numerals, should appear in India ink directly on the photographs and, if possible, should be in the lower right-hand corner of each photograph. These numbers should be no larger than \( \frac{1}{4} \) inch. Wax-based lettering such as PRES-TYPE or LETTRA-SET is discouraged because of its tendency to crumble and adhere to vinyl overlays. Tissue overlays on plates are a necessary protection for figures. The first author's name should be given in pencil on the reverse side of each plate.

Figure legends. An appropriate legend for each figure, including stains and magnifications where applicable, is required. Any abbreviations or reference points on a figure should be explained in the legend. All attempts will be made to place legends under the plates to which they refer. To facilitate proper layout, authors may wish to keep their plates to 7\( \frac{1}{4} \) x 8\( \frac{1}{2} \) inches.

Abbreviations

Abbreviations are in general a hindrance to readers in fields other than that of the author(s), to abstractors, and to scientists in foreign countries. It is therefore the policy of this Journal, which publishes material on several subspecialties of cancer research, to limit their use to an absolute minimum. Short terms need not be abbreviated, e.g., daunomycin, folate, vincristine. Abbreviations are not to be used in titles, but running titles may carry abbreviations for purposes of brevity. Abstracts may contain abbreviations for terms mentioned many times in that section but their identification is mandatory.

Authors should follow the recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature (see section below on Terminology). All nonstandard abbreviations should be identified in an inclusive abbreviation footnote to the first such abbreviation after the Abstract.

Abbreviations that form recognizable words, such as EAT and MOPS are not acceptable.

Standard Abbreviations. Authors may use, without definition, the abbreviations in the following lists.

\[
\begin{align*}
NAD^+, \quad & \text{nicotinamide adenine dinucleotide} \\
NADP^+, \quad & \text{nicotinamide adenine dinucleotide} \\
\quad (\text{DPH}^+, \ \text{TPH}^+), \quad & \text{and their reduced forms are not acceptable.} \\
\quad \text{CoA, acyl-CoA} \\
\quad \text{AMP, GMP, IMP, UMP, CMP, TMP} \\
\quad \text{ADP, etc.} \\
\quad \text{ATP, etc.} \\
\quad \text{dAMP, dGMP, dIMP} \\
\quad \text{RNA, DNA} \\
\quad \text{RNase, DNase} \\
\quad \text{mRNA} \\
\quad \text{nRNA} \\
\quad \text{rRNA} \\
\quad \text{tRNA} \\
\quad \text{P, PP} \\
\end{align*}
\]

\[
\begin{align*}
\quad \text{coenzyme A and its acyl derivatives} \quad & \text{(e.g., acetyl)} \\
\quad \text{the 5'-phosphates of ribosyladenine, -guanine, -inosine, -uracil,} \\
\quad \text{-cytosine, and -thymine} \\
\quad \text{the 5'-(pyro)-diphosphates of adenosine, etc.} \\
\quad \text{the 5'-(pyro)-triphosphates of adenosine, etc.} \\
\quad \text{the 5'-phosphates of 2'-deoxyribosyladenine, etc.} \\
\quad \text{ribonucleic acid, deoxyribonucleic} \\
\quad \text{acid} \\
\quad \text{ribonuclease, deoxyribonuclease} \\
\quad \text{messenger RNA} \\
\quad \text{nuclear RNA} \\
\quad \text{ribosomal RNA} \\
\quad \text{transfer RNA (sRNA is not recommended for RNA preparations} \\
\quad \text{that accept amino acids.)} \\
\quad \text{orthophosphate, pyrophosphate}
\end{align*}
\]
Instructions for Authors

Tris
tris(hydroxymethyl)aminomethane
EDTA
ethylenediaminetetraacetate
POPOP
1,4-bis[2-(5-phenyloxazolyl)]benzene
PPO
diethylaminoethyl, triethylaminoethyl
DEAE, TEAE
diethylaminoethyl, triethylaminoethyl
UV, IR
ultraviolet light, infrared
RBC, WBC
red blood cell(s), white blood cell(s)

Other Standard Abbreviations

Units of Concentration
molar (moles/liter) M (not used for moles)
millimolar (millimoles/liter) mM (preferred to 10⁻³ M)
micromolar (micromoles/liter) µM (preferred to 10⁻⁶ M)
nanomolar nM (not µM)
picomolar pM (not µM)
The expression mg % should be avoided; weight concentrations should be given as g per ml, g per 100 ml, g per liter, etc.

Units of Length, Area, Volume, Mass, Time

The abbreviations below are correct for both singular and plural forms of each term.
meter m
centimeter cm
square centimeter sq cm
millimeter mm
micrometer (not micron) µm (not µ)
nanometer nm (not mµ)
picometer (not micromicron) pm (not µm)
Angstrom (0.1 nm) Å
liter not abbreviated
milliliter ml (use instead of cc or cm³)
microliter µl (not λ)
gram g
milligram mg
microgram µg (not γ)
kilogram kg
hour hr
minute min
second sec

Physical and Chemical Units
retardation factor Rf
acceleration of gravity g
sedimentation coefficient s
sedimentation coefficient in water at 20° S₂₀,w
degree Celsius (Centigrade) ° (not °C)
degree Kelvin K
diffusion coefficient D
equilibrium constant K
inhibition constant Kᵢ
Michaelis constant KM
maximum velocity Vmax

Others
mole mol
Curie Ci
equivalent eq
counts per minute cpm
disintegrations per minute dpm
revolutions per minute rpm
volt V
Svedberg unit S
absorbance A (not O.D.)
probability p
roentgen R
standard deviation S.D.
standard error of the mean S.E.
logarithm (Briggsian) log
logarithm (natural) ln
entropy S

in chemical compounds
ortho o
meta m
para p
secondary sec
tertiary tert

routes of administration
intramuscular i.m.
intraperitoneal i.p.
intravenous i.v.
oral p.o.
subcutaneous s.c.

Terminology

Approved terms and abbreviations for chemical substances have been published in Collected Tentative Rules and Recommendations of the Commission on Biochemical Nomenclature IUPAC-IUB. The Second Edition (1975) is available for $3 (to accompany order) from the American Society of Biological Chemists, Inc., 9650 Rockville Pike, Bethesda, Maryland 20014. Individual listings have appeared in many journals as follows:

1. for abbreviations and symbols (general). European J. Biochem., 74: 1-6, 1977
8. for synthetic modifications of natural peptides, J. Biol.
9. for lipids, Lipids, 12: 455–468, 1977
10. for cyclitols, European J. Biochem., 57: 1–7, 1975
11. for steroids, Biochemistry, 8: 2227–2242, 1969, and its
   amendments, Biochemistry, 10: 4994–4995, 1971
12. for iron-sulfur proteins, J. Biol. Chem., 248: 5907–5908,
    1973
13. for carbohydrates, J. Biol. Chem., 247: 613–634, 1972,
    and European J. Biochem., 25: 4, 1972
    and revision, Biochemistry, 14: 1803, 1975
15. for α-amino acids, Biochemistry, 14: 449–462, 1975
16. for peptide hormones, J. Biol. Chem., 250: 3215–3216,
    1975
17. for human immunoglobulins, European J. Biochem.,
    45: 5–6, 1974
18. for quinones with isoprenoid side chains, European J.
    Biochem., 53: 15–18, 1975
19. for folic acid and related compounds, J. Biol. Chem.,
    241: 2991–2992, 1966
21. for multiple forms of enzymes, J. Biol. Chem., 252:
    5939–5941, 1977
22. for phosphorus-containing compounds of biochemical
    2230, 1977
23. for fundamental stereochemistry, European J. Bio-
    chem., 18: 151–170, 1971
24. for immunoglobulins (WHO document), J. Biol. Chem.,
    245: 3033–3034, 1970
    44, 1970
26. for the major human histocompatibility complex (HLA),

Isotopically Labeled Compounds. A radioactive nuclide
is indicated by its mass number as a superscript to the left
of the symbol (32P); when written out, it should cor-
respond to the spoken word (phosphorus-32).

In an isotopically labeled compound, the isotopic prefix
should be placed in square brackets and immediately pre-
cede the name (word) to which it refers, as in [14C]-
thymidine, [α-14C]leucine, L-[methyl-14C]methionine, [PH]-
3-hydroxykynurenine. When more than one position in a
substance is labeled by means of the same isotope and
the positions are not indicated, the number of labeled
atoms is added as a subscript to the right of the element,
as in [14C]glycine acid. The symbol U indicates uniform
labeling and G, general labeling, e.g., [U-14C]glucose
(where the 14C is uniformly distributed among all six posi-
tions) and [G-14C]glucose (where the 14C is distributed
among all six positions, but not necessarily uniformly).

The isotopic prefix precedes that part of the name to
which it refers, as in sodium [14C]formate, iodo[14C]acetic
acid, 1-aminoo[14C]methylcyclopentanol, α-naphth[14C]ic
acid, 2-aminoo[14C]fluorene, fructose 1,6-[32P]-
bisphosphate, 17β-[3H]estradiol. Terms such as “131I-labeled
albumin” should not be contracted to “131Ialbumin” (since
native albumin does not contain iodine), and “14C-labeled
amino acids” should similarly not be written as “14Camino
acids” (since there is no carbon in the amino group).

When isotopes of more than one element are introduced,
their symbols should be arranged in alphabetical order,
e.g., [3-14C; 2,3-D; 15N]serine. Deuterium and tritium may be
designated as δH and δD or as D and T, respectively.

When not sufficiently distinguished by the foregoing
means, the positions of isotopic labeling are indicated by
Arabic numerals, Greek letters, or prefixes in italics, as
appropriate; these are to be placed within square brackets
to appear before the symbol of the element concerned and
are attached to it by a hyphen. Examples of this style are [1-
14C]alanine, L-[2-14C]leucine or L-[α-14C]leucine, [carboxy-
14C]leucine, [2,3-14C]maleic anhydride, [3,4-14C, 35S]methio-
nine, L-[methyl-14C]methionine. The symbol indicating
configuration always precedes the bracketed isotope, and a hy-
phen is used to separate if from the brackets, e.g., D-[14C]-
glucose; L-[1-14C]leucine.

The same rules apply when the labeled compound is
designated by a standard abbreviation or symbol other than
the atomic symbol, e.g., [α-32P]ATP, [32P]CMP, or [32P]IdUrd.
The square brackets are not to be used, however, with
atomic symbols, or when the isotopic symbol is attached to
a word that is not a specific chemical name, abbreviation,
or symbol. Proper usage here is: 14CO2, H2O, H235SO4, 32P,
131I-labeled, 3H-ligands, 3C-steroids.

Enzymes. Authors should use the Recommended (trivial)
Name given by the IUB Commission on Enzyme Nomen-
clature Recommendations (1972) of the International Union
of Pure and Applied Chemistry and the International Union
of Biochemistry (Elsevier Publishing Company, Amsterdam,
1973). In some cases the Systematic Name or the reaction
catalyzed should also be included. It is strongly recom-
manded that the Enzyme Commission number be stated at
first mention.

For information on isozyme nomenclature, consult the
"Collective Tentative Rules . . . " mentioned above or the
specific listing published in the Journal of Biological Chem-
istry (reference above).

Histones. Histone nomenclature should conform to the
following system proposed at a Ciba conference held on
April 4–5, 1974, in London: the six histone fractions are to
be labeled H1, H1a, H2A, H2B, H3, and H4, rather than F1,
F1a, F2a2, F2b, F3, and F2a1, respectively.

Inbred Strains. Designations for inbred mouse strains
should conform to the guidelines in "Standardized Nomen-
clature for Inbred Strains of Mice: Sixth Listing," Cancer
Res., 36: 4333–4377, 1976, prepared by Joan Staats for the
Committee on Standardized Nomenclature for Mice; for des-
ignations of inbred strains of rats, please refer to "Standard-
ized Nomenclature for Inbred Strains of Rats: Fourth List-
ing," Michael Festing and Joan Staats, Transplantation,

Outbred Animal Stocks. Nomenclature for outbred lab-
oratory animals should conform to that recommended by the
Committee on Nomenclature, Institute of Laboratory Animal
Resources: "A Nomenclature System for Outbred Animals,"

Drugs. Generic names of drugs are preferred; a propri-
tary name may be used only after the first mention of the
generic name and should be avoided in titles unless both
names can easily be listed. If a foreign proprietary name is
used, the name of the comparable U. S. product should be given. When there is no generic name for a drug, authors should give the chemical name or formula or a description of the active ingredients.

Authors should refer to the formally adopted generic names listed in AMA Drug Evaluations (Second Edition, 1973), The United States Pharmacopoeia (USP, Nineteenth Revision, 1975), National Formulary (NF, Fourteenth Edition, 1975), 1st Supplement of USP XIX and NF XIV (1975), and USAN and the USP Dictionary of Drug Names (1975). In addition, the Council on Drugs reports in The Journal (New Names) drug names adopted by the USAN (United States Adopted Names) Council. These monographs include both the generic and proprietary names for the newest drugs, usually prior to their publication elsewhere.

Tumors. Tumors used in experimental investigations should be clearly described and identified in acceptable terminology. If these tumors are well known and have been identified in previous publications, extended descriptions and photomicrographs are unnecessary.

General. The composition of all solutions and buffers should be specified in sufficient detail so that the concentration of each component can be determined. The word "saline" should be replaced by "NaCl solution," along with the exact concentration. Inexact terms such as "physiological saline" or "phosphate-buffered saline" are not permitted; exact contents and concentrations should be given.

Decimals are preferred to fractions; the form 0.01, not .01, is required in text, tables, and charts.

Ionic charge should be designated by a superscript immediately following the chemical symbol, e.g., Mg++, S4. Advice on biochemical nomenclature is readily available from Dr. Waldo E. Cohn, Director, NAS-NRC Office of Biochemical Nomenclature, Biology Division, Oak Ridge National Laboratory, Box Y, Oak Ridge, Tennessee 37380.

Alterations in Proof

To expedite publication of accepted articles, the Journal provides authors in the U. S. and Canada with page proofs only. Authors residing outside the U. S. and Canada will receive galley proofs only; their page proofs will be read in the Editorial Office. Extensive alterations in proof require revised pagination, thus leading to sharply increased costs and delays in publication. Such alterations will necessarily be charged to the authors. We therefore urge our contributors to proofread and edit their manuscripts carefully before submission. The Editors retain the right to question minor stylistic alterations and major alterations that might affect the scientific content of the paper. The authors may or may not be contacted, depending on the nature of corrections in page proof, or if proof is not returned to the Editorial Office within 48 hours of receipt, it may be necessary to reschedule the paper for a subsequent issue.

Reprints

Reprint order forms are sent to authors along with their proofs. If the form has been omitted inadvertently from the shipment, the Editorial Office should be contacted immediately. Orders are to be placed prior to publication according to the schedule of prices given on the form. Reprint order forms must be returned to the Editorial Office along with the corrected proof; purchase orders should be issued and sent directly to Waverly Press, Inc., Mount Royal & Guilford Avenues, Baltimore, Maryland 21202. Requests for additional reprints should be addressed to Waverly Press, Inc. Reprints ordered after the Journal has been released to press will be more costly.

Reprints are normally shipped 4 to 6 weeks after publication of the Journal.

It is helpful to the reader if a footnote is included in the paper indicating to which author reprint requests should be addressed.

Copyright

Under the new copyright law (PL 94-553) which is effective January 1, 1978, copyright for written material is vested in the author from the moment of its creation and remains the property of the author until legally transferred. For this reason it has become necessary to require that all authors who wish to publish in Cancer Research formally transfer copyright to the proprietor of the Journal, namely, Cancer Research, Inc., the publishing subsidiary of the American Association for Cancer Research. It is understood by this transfer that the authors relinquish all exclusive rights of copyright ownership, including the rights of reproduction, derivation, distribution, and display. However, the Journal will continue its policy of allowing authors (or others with the permission of the authors) to include the copyrighted material in reviews, books, or subsequent papers, upon written request to the Editor. It is understood in conveying copyright that the authors have not published this material elsewhere, either in whole or in part (except in abbreviated form as a preliminary communication), and that they have neither concluded previous negotiations nor initiated pending negotiations for copyright of this material.

When a manuscript has been written by two or more authors, one of them will be designated senior author and will negotiate copyright transfer in the name of all of the authors.

The federal government has determined that it has a non-exclusive right to publish or republish material developed from work performed under federal grant-supported projects. Therefore, copyrights for such works are subject to this restriction. Since the federal government does not recognize private copyright for work performed by its employees as part of their official duties, the Journal will accept papers from government laboratories without copyright transfer, provided that the authors abide by the same provisions required of other authors.

Appropriate forms for transfer of copyright will be sent routinely with acknowledgement of receipt of manuscripts. They may also be requested from the Cancer Research Editorial Office. The Journal will not accept a paper unless the form is properly filled out and signed.

Advertising

Starting with this volume, the Journal will accept advertising. This decision was reached after careful con-
sideration by the Board of Directors of the American Association for Cancer Research. It is hoped that advertising will provide a substantial source of additional income to help defray steadily increasing costs of publication and keep subscription rates at a reasonable level. In this practice, the Journal is following that of many other journals in the biomedical sciences.

Advertisement insertion orders and copy must be received 60 days prior to the month of issue in which the advertisement is to be published. The Journal is mailed on the 20th of the month preceding the month of issue. Inquiries regarding advertising should be directed to: Donald H. Nichols, Vice President, Journal Sales, Waverly Press, Inc., 428 East Preston St., Baltimore, Maryland 21202. Telephone: 301/528-4280.

Reproduction Permission

Reproduction permission will usually be granted by Cancer Research, Inc., owner of the copyright, for legitimate purposes. Requests for reproduction of published material, along with a brief description of intended use, should be made by writing to the Editor. Third parties should obtain the approval of the authors before corresponding with the Editor.

Subscriptions and Business Inquiries

All subscriptions and business matters are handled by the publisher, Waverly Press, Inc., 428 East Preston Street, Baltimore, Maryland 21202. The publisher should be notified of changes of address 60 days in advance; subscribers should give both their old and new addresses. Complete, up-to-date information on subscriptions appears in the front of each monthly issue.

No responsibility is accepted by the Editors, by Cancer Research, Inc., by the American Association for Cancer Research, Inc., or by the publishers of Cancer Research for opinions expressed by the contributors or for the content of advertisements.

Several stylistic items are commonly overlooked by authors, thus entailing wasted time and expense at the processing and publication stages. Authors may find it helpful to refer to the following checklist before transmitting manuscripts to our office.

1. Manuscript submitted in quadruplicate with at least two sets of original illustrations
2. Grant information, if appropriate, supplied in a footnote to the title
3. Exact affiliation of each author given
4. Running title provided, not to exceed 50 typed characters
5. Abstract included
6. All nonstandard abbreviations defined in an inclusive footnote
7. Exact location [city and state (or country)] for sources of special chemicals or preparations supplied
8. All references listed in alphabetical order and typed double spaced
9. Instructions followed regarding size of lettering on charts
10. Electron micrographs mounted on heavy white cardboard, with photograph dimensions not to exceed 18.4 x 22.4 cm (7 1/4 x 9 inches)
AUTHOR INDEX

January 1978

Anderson, L. M., 137
Antonson, K., 177
Arcos, J. C., 226
Argus, M. F., 226
Atkins, D., 23
Au, J. L., 210

Baldwin, R. W., 69
Barth, R. F., 32
Becker, F. F., 163
Betzi, E. H., 52
Bianchi, V., 110
Bigner, D. D., 74
Blakemore, W. S., 193
Bodgen, A. E., 59
Boguski, M. S., 88
Boniver, J., 52
Bowen, D., 219
Brooks, W. H., 74
Brown, C. E., 159
Budinger, J. M., 137
Buttignol, M., 110

Chen, C-h. B., 215
Chou, T-H., 181
Clifton, K. H., 189
Cobb, W. R., 59
Conrad, H. E., 185
Courteze, R., 13
Courtoy, R., 52
Crowley, J., 189

De Lorenzo, F., 13
Dray, S., 223
Erickson, J., 177
Evans, W. H., 130

Feldmann, G., 16
Fisher, B., 38
Fox, P., 65
Frank, J. J., 88
Frayssinet, C., 16
Freedman, S. O., 6

Garcia-Suarez, S., 142
Gebhardt, M., 38
Gold, P., 6
Goldman, I. D., 219
Good, R. A., 137

Gosalvez, M., 142
Gould, M. N., 189
Greager, J. A., 69
Guesnon, J., 16
Gulkin, T. A., 59

Hale, A. H., 185
Hammonds, J. C., 23
Hanlon, J., 38
Hanna, M. G., Jr., 204
Hatzfeld, A., 16
Hecht, S. S., 215
Heft, K., 83
Himmelhoch, S. R., 130
Hoffmann, D., 215
Hsu, C. K., 130
Hunt, N. H., 23

Jirtle, R., 189
Johnson, R. K., 59

Kahn, C. R., 94
Kelton, D. E., 59
Kessel, D., 181
Khilanani, P., 181
Kimura, J., 78
Kleinman, R., 223
Krupey, J., 6
Kwock, L., 83

Labitan, A., 6
Leatherland, J. F., 149
Leonard, J. G., 185
Levis, A. G., 110
Levy, C. C., 88
Lin, P-S., 83
Linta, J., 36
Lippman, M. E., 94
Loader, K. R., 168
Lopez-Alarcon, L., 142

Mage, M. G., 130
Markesbery, W. R., 74
Maronpot, R. R., 137
Martin, T. J., 23
Michelangeli, V. P., 23
Minkel, D. T., 117, 124
Moccia, R., 149
Monaco, M. E., 94

Nagel, D., 177
Nagourney, R. A., 65
Nakayasu, M., 103
Nathanial, E. J. H., 168
Neuwelt, E. A., 88

Osborne, C. K., 94
O'Toole, C., 199

Patil, K., 177
Perin, A., 1
Petering, D. H., 117, 124
Peters, L. C., 204
Procter-Appich, K., 88

Roll, D. E., 185
Roszman, T. L., 74

Sadee, W., 210
Saffar, E., 38
Saryan, L. A., 124
Sato, S., 103
Schapira, F., 16
Schein, P. S., 65
Sessa, A., 1
Shimamura, S., 103
Shortland, J. R., 23
Shuster, J., 6
Silengo, L., 13
Simar, L. J., 52
Singh, I., 193
Singla, O., 32
Smith, G. H., 130
Sofen, H., 199
Sonstegard, R., 149
Sponza, G., 110
Staiano, N., 13
Sugimura, T., 103

Takeuchi, T., 103
Toh, Y. C., 42
Toth, B., 177
Tsang, K. Y., 193

Wallach, D. F. H., 83
Warren, S., 159
Weber, M. J., 185
White, J. C., 219
Wong, H. C. G., 6
Wu, A. T., 210
With the steady improvement in the therapy of cancer, and consequent increase in the number of 5-year survivals, our programs reflect increasing concern with the future of the cancer patient—with the quality of his survival.

High priority is being given to the rehabilitation of cancer patients—those having had mastectomies, colostomies, laryngectomies, amputations, and other drastic treatments for cancer.

Our "Reach to Recovery" program is a dramatic example. This program helps the physician meet many special needs of the postmastectomy patient on the road to total recovery. Patients receive psychological reassurance and practical help from women who have had the same surgery.

The laryngectomee also receives the benefit of our rehabilitation program. Supported by the Society, the International Association of Laryngectomees, through its local IAL clubs, provides such services as individual and group speech therapy, psychological counseling, visits to new patients, safety training, public education and social activities.

Our rehabilitation programs not only give heart and help to patients but provide the physician with vital aids necessary to improve the quality of survival.

American Cancer Society